Novo Nordisk to buy Catalent for $16.5 billion
BLOOMINGTON - Novo Nordisk Foundation announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. They hope to conclude the deal by the end of the year. Tra ...